Nine Diagnostics was selected as one of two recipients of the 2024 Novo Nordisk Golden Ticket, a competitive award program run jointly by Novo Nordisk’s Bio Innovation Hub and LabCentral that recognizes early-stage life sciences companies advancing innovative approaches to healthcare challenges. Nine Diagnostics was selected from a group of five finalists also including Fletcher Biosciences, Ilios Therapeutics, Lilium Therapeutics, and Zeal Therapeutics. The Golden Ticket provides recipients with a $50,000 credit toward lab space at LabCentral’s Cambridge facilities, access to shared scientific infrastructure, and a direct connection to Novo Nordisk’s innovation team for scientific and drug development support. The award also includes mentorship and collaboration opportunities within the Cambridge life sciences ecosystem.
“We are deeply honored and excited to receive this recognition from Novo Nordisk,” said Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics. “This recognition validates our vision and the potential impact of our AI-enabled nanosensor technology. We are positioned to accelerate the development of our platform and bring us one step closer to achieving our vision of functional precision medicine.”
Stanislav Piletsky, PhD, a postdoctoral researcher in the Heller Lab at Memorial Sloan Kettering Cancer Center (MSKCC), added: “This Golden Ticket is a major stepping stone for us. It provides a unique opportunity to refine our technology and expand our impact, particularly in areas such as cancer diagnostics.”
The Golden Ticket reflects the Bio Innovation Hub’s broader mission of accelerating cardiometabolic and rare disease innovation through partnerships across the Cambridge life sciences ecosystem, and LabCentral’s role as a launchpad connecting early-stage biotech founders with shared lab infrastructure and a dense peer network of startups. The nanosensor platform recognized by the award was developed during founder postdoctoral research in the Heller Lab at MSKCC, and forms the scientific foundation of Nine Diagnostics, co-founded in 2024 by Freddy T. Nguyen, MD, PhD, Daniel A. Heller, PhD, and Mijin Kim, PhD.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.
About the Novo Nordisk Bio Innovation Hub
The Novo Nordisk Bio Innovation Hub is a cross-disciplinary innovation unit based in Cambridge, MA. It fosters partnerships across the life sciences ecosystem to accelerate the development of therapies for cardiometabolic and rare diseases, working with biotech, academia, and healthcare innovators.
About LabCentral
LabCentral is a nonprofit launchpad supporting life sciences and biotech startups in Cambridge, MA. It offers shared lab space, programming, and networking to help early-stage companies bring their innovations to market.